(403) 770-2469 info@marvelbiotechnology.com
Segovia Beta Testing
  • About Us
  • The Technology
    • MB-204
    • Non-Hallucinogenic Neuroplasticity Program
  • Investors
  • News
    • Latest Posts
    • Latest News
  • Contact
Select Page

Marvel Biosciences Announces Proxy Tabulation and Shareholder Meeting Results

Mar 2, 2022 | News

Calgary, Alberta–(Newsfile Corp. – February 15, 2022) – Marvel Biosciences Corp. (TSXV: MRVL) and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company“ or “Marvel“), is pleased to report the proxy tabulation (“Tabulation“) from Odyssey...

Marvel Biosciences Provides Corporate Update as it Enters a Significant Value Creating Phase

Mar 2, 2022 | News

Calgary, Alberta–(Newsfile Corp. – February 8, 2022) –  Marvel Biosciences Corp. (TSXV: MRVL) and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”) is pleased to provide a corporate update on the operations of the...

Recent Posts

  • Marvel Biosciences Announces Proxy Tabulation and Shareholder Meeting Results
  • Marvel Biosciences Provides Corporate Update as it Enters a Significant Value Creating Phase
Copyright 2022 Marvel Biosciences Corp. All rights reserved.